# Adma Biologics, Inc.: overview

ADMA · Nasdaq · CIK 1368514 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/adma.md) · [Financials](/companies/adma/financials.md) · [Filings](/companies/adma/filings.md) · [Insiders](/companies/adma/insiders.md)

Latest reported revenue: [$124.4m](/filings/0001140361-26-031445.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001140361-26-031445).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [120](/filings/0001140361-25-040578.md) | [118 d](/filings/0001140361-26-006815.md) | [115](/filings/0001140361-26-019336.md) | [122](/filings/0001140361-26-031445.md) | [134](/filings/0001140361-25-040578.md) | [139 d](/filings/0001140361-26-006815.md) | [114](/filings/0001140361-26-019336.md) | [124](/filings/0001140361-26-031445.md) |
| Gross margin | % | [49.8%](/filings/0001140361-25-040578.md) | [53.9% d](/filings/0001140361-26-006815.md) | [53.2%](/filings/0001140361-26-019336.md) | [55.1%](/filings/0001140361-26-031445.md) | [56.3%](/filings/0001140361-25-040578.md) | [63.8% d](/filings/0001140361-26-006815.md) | [70.5%](/filings/0001140361-26-019336.md) | [69.4%](/filings/0001140361-26-031445.md) |
| Operating margin | % | [33.1%](/filings/0001140361-25-040578.md) | [32.6% d](/filings/0001140361-26-006815.md) | [30.4%](/filings/0001140361-26-019336.md) | [35.1%](/filings/0001140361-26-031445.md) | [38.0%](/filings/0001140361-25-040578.md) | [45.1% d](/filings/0001140361-26-006815.md) | [50.9%](/filings/0001140361-26-019336.md) | [42.2%](/filings/0001140361-26-031445.md) |
| Net margin | % | [30.0%](/filings/0001140361-25-040578.md) | [95.2% d](/filings/0001140361-26-006815.md) | [23.4%](/filings/0001140361-26-031445.md) | [28.1%](/filings/0001140361-26-031445.md) | [27.1%](/filings/0001140361-25-040578.md) | [35.5% d](/filings/0001140361-26-006815.md) | [39.6%](/filings/0001140361-26-031445.md) | [30.4%](/filings/0001140361-26-031445.md) |
| Diluted EPS | $ per share | [0.15](/filings/0001140361-25-040578.md) | not reported | [0.11](/filings/0001140361-26-019336.md) | [0.14](/filings/0001140361-26-031445.md) | [0.15](/filings/0001140361-25-040578.md) | not reported | [0.19](/filings/0001140361-26-019336.md) | [0.16](/filings/0001140361-26-031445.md) |
| Free cash flow | $m | [24.0 d](/filings/0001140361-25-040578.md) | [47.5 d](/filings/0001140361-26-006815.md) | [(24.4)](/filings/0001140361-26-019336.md) | [18.7 d](/filings/0001140361-26-031445.md) | [(1.1) d](/filings/0001140361-25-040578.md) | [34.6 d](/filings/0001140361-26-006815.md) | [55.7](/filings/0001140361-26-019336.md) | [27.3 d](/filings/0001140361-26-031445.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [80.9](/filings/0001140361-24-010147.md) | [154](/filings/0001140361-25-009257.md) | [258](/filings/0001140361-26-006815.md) | [426](/filings/0001140361-26-006815.md) | [510](/filings/0001140361-26-006815.md) |
| Gross margin | % | [1.4%](/filings/0001140361-24-010147.md) | [22.9%](/filings/0001140361-25-009257.md) | [34.4%](/filings/0001140361-26-006815.md) | [51.5%](/filings/0001140361-26-006815.md) | [57.4%](/filings/0001140361-26-006815.md) |
| Operating margin | % | [(72.1%)](/filings/0001140361-24-010147.md) | [(25.5%)](/filings/0001140361-25-009257.md) | [8.4%](/filings/0001140361-26-006815.md) | [32.6%](/filings/0001140361-26-006815.md) | [37.5%](/filings/0001140361-26-006815.md) |
| Net margin | % | [(88.5%)](/filings/0001140361-24-010147.md) | [(42.8%)](/filings/0001140361-25-009257.md) | [(10.9%)](/filings/0001140361-26-006815.md) | [46.4%](/filings/0001140361-26-006815.md) | [28.8%](/filings/0001140361-26-006815.md) |
| Diluted EPS | $ per share | [(0.51)](/filings/0001140361-24-010147.md) | [(0.33)](/filings/0001140361-25-009257.md) | [(0.13)](/filings/0001140361-26-006815.md) | [0.81](/filings/0001140361-26-006815.md) | [0.60](/filings/0001140361-26-006815.md) |
| Free cash flow | $m | [(126)](/filings/0001140361-24-010147.md) | [(73.4)](/filings/0001140361-25-009257.md) | [4.0](/filings/0001140361-26-006815.md) | [110](/filings/0001140361-26-006815.md) | [27.8](/filings/0001140361-26-006815.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/adma/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $321.0m | 38,355,684 |  | Added +1,524,910 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $143.3m | 17,116,022 |  | Added +3,031,817 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $84.6m | 10,103,809 |  | Reduced −203,062 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $84.4m | 10,088,490 |  | Added +1,219,833 |
| [Rubric Capital Management LP](/funds/1687509.md) | 2026-06-30 | $78.2m | 9,339,414 |  | Added +7,530,006 |
| [Capital Research Global Investors](/funds/1422848.md) | 2026-06-30 | $73.3m | 8,756,374 |  | Reduced −2,434,742 |
| [FIRST TRUST ADVISORS LP](/funds/1125816.md) | 2026-06-30 | $65.3m | 7,798,351 |  | Added +7,438,134 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $50.7m | 6,059,984 |  | Added +235,868 |
| [Caligan Partners LP](/funds/1727492.md) | 2026-06-30 | $47.9m | 5,725,007 |  | Added +968,496 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $44.1m | 5,274,597 |  | Added +4,713,770 |

## Recent filings

[All 970 filings](/companies/adma/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 17:16 ET | [10-Q](/filings/0001140361-26-031445.md) | Quarterly report, period 2026-06-30 | 0001140361-26-031445 |
| 2026-08-05 | 16:10 ET | [8-K](/filings/0001140361-26-031423.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-031423 |
| 2026-06-02 | 16:05 ET | [8-K](/filings/0001140361-26-023705.md) | 5.07 Shareholder vote results | 0001140361-26-023705 |
| 2026-05-06 | 17:16 ET | [10-Q](/filings/0001140361-26-019336.md) | Quarterly report, period 2026-03-31 | 0001140361-26-019336 |
| 2026-05-06 | 16:10 ET | [8-K](/filings/0001140361-26-019295.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-019295 |
| 2026-05-04 | 07:05 ET | [8-K](/filings/0001140361-26-018667.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-018667 |
| 2026-04-15 | 16:30 ET | [DEF 14A](/filings/0001140361-26-014799.md) | Proxy statement, period 2026-06-02 | 0001140361-26-014799 |
| 2026-03-27 | 07:05 ET | [8-K](/filings/0001140361-26-011569.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-011569 |
| 2026-03-02 | 07:05 ET | [8-K](/filings/0001140361-26-007230.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-007230 |
| 2026-02-25 | 17:16 ET | [10-K](/filings/0001140361-26-006815.md) | Annual report, period 2025-12-31 | 0001140361-26-006815 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001140361-26-006815.md), filed Feb 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/6e43afd3-07b1-4274-8737-02569b0726b8)

## About the filer

- CIK: 1368514
- Tickers: ADMA
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.